SCHEMBL4257635

SCHEMBL4257635

CCCCN1CCN(c2cc(C(=O)O)ccc2C2CCC(C(C)(C)C)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.42
DRD3 P35462 4/20 0.42
HTR1A P08908 3/20 0.41
HTR2A P28223 3/20 0.41
DRD4 P21917 2/20 0.41
HTR2C P28335 1/20 0.41
HRH1 P35367 3/20 0.39
HRH2 P25021 1/20 0.39
CYP2J2 P51589 2/20 0.39
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
KCNH2 Q12809 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
ACHE P22303 1/20 0.37
HTR4 Q13639 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13806175 0.91 DRD2 (0.42) DRD2DRD3HTR1AHTR2ADRD4
Hydrochloric Acid SCHEMBL4855101 0.91 MEN1 (0.42) DRD2DRD3HTR1AHTR2ADRD4
Hydrochloric Acid SCHEMBL4258530 0.90 DRD2 (0.41) DRD2DRD3HTR1AHTR2ADRD4
SCHEMBL13806178 0.89 DRD2 (0.41) DRD2DRD3HTR1AHTR2ADRD4
SCHEMBL4408657 0.89 HTR7 (0.43) DRD2DRD3HTR1AHTR2ADRD4
Hydrochloric Acid SCHEMBL4253712 0.88 DRD2 (0.40) DRD2DRD3HTR1AHTR2ADRD4
Hydrochloric Acid SCHEMBL4408654 0.88 HTR7 (0.42) DRD2DRD3HTR1AHTR2ADRD4
SCHEMBL4854200 0.86 DRD3 (0.41) DRD2DRD3HTR1AHTR2ADRD4
SCHEMBL13806179 0.86 HRH3 (0.42) DRD2HTR2AHRH1HRH2THRB
Hydrochloric Acid SCHEMBL5053427 0.85 HRH3 (0.42) DRD2HTR2AHRH1HRH2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102040552-A 1, 2-di (cyclic group) substituted benzene derivative EISAI R&D MAN CO LTD 2011-05-04 CN disclosed
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-18 US disclosed
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-18 US disclosed
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-18 US disclosed
CN-101175723-A 1, 2-di (cyclic group) substituted benzene derivative EISAI R&D MAN CO LTD (JP) 2008-05-07 CN disclosed
EP-1892238-A1 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-02-27 EP disclosed
EP-1892238-A1 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-02-27 EP disclosed
US-20060281747-A1 1,2-di(cyclic) substituted benzene derivatives EISAI R&D MANAGEMENT CO., LTD. 2006-12-14 US disclosed
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE CCR10, H1-10, VCAM1 DRD2 746/4885DRD3 638/4885HTR1A 721/4885
US-20060281747-A1 1,2-di(cyclic) substituted benzene derivatives CCR10, H1-10, CXCL10 DRD2 768/4885DRD3 610/4885HTR1A 769/4885
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds HRH3, CCR10, HRH1 DRD2 563/4885DRD3 224/4885HTR1A 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.